Urine test may help identify autism risk in children – News-Medical

85

The Microbially-Derived Metabolite (MDM) System

Early detection of autism spectrum disorder often relies on behavioral assessments that can be slow or subjective. To accelerate this process, researchers at Arizona State University have introduced a biological screening tool designed to find markers of autism in a child’s urine long before traditional assessments might catch them. The tool, known as the “Microbially-Derived Metabolite (MDM) System,” targets 17 specific microbial metabolites. These are small molecules produced by microorganisms in the gut that eventually enter the bloodstream and are excreted through the urinary system. Rather than looking for a single “autism marker,” the system assigns a score based on how many of these metabolites exceed a typical reference range. The results are striking: between 80% and 90% of children with autism in the study exhibited extremely high levels of at least one of these microbially derived metabolites.

Mapping the Gut-Brain Connection

The biological pattern discovered by the team suggests a deep link between gut health and neurological development. The metabolites identified in the urine are not random; they are tied to key amino acids—tyrosine, tryptophan, and phenylalanine—which are essential to neurotransmitter pathways. Beyond these amino acids, the researchers found compounds connected to yeast and fungal activity. This indicates that the biological diversity within autism is often reflected in the gut microbiome. By identifying these specific chemical signatures, clinicians may eventually be able to move toward targeted interventions, such as therapies aimed at restoring a healthy gut microbiome to support brain function.

Clinical Accuracy and Sample Constraints

The initial trials produced high-performance metrics that suggest the test is a highly reliable filter for autism risk. The study reported 90% sensitivity, meaning it correctly identified 90% of the children with autism, and 100% specificity, meaning it did not misidentify a single typically developing child as having autism. These results were drawn from a study group of 99 children:

• 52 children diagnosed with autism spectrum disorder.
• 47 typically developing children.
• Age range: 2 to 11 years.
• Locations: Participants were drawn from Arizona, Massachusetts, Tennessee, and Texas.

While the 100% specificity is a significant win, the research team acknowledges the moderate sample size. Further validation is currently underway to ensure these results hold across larger and more diverse populations.

From Visual Cues to Molecular Screening

Using urine as a diagnostic medium is a long-standing medical tradition, though the ASU study represents a leap from visual observation to molecular analysis. Traditionally, as Cleveland Clinic notes, urine is primarily water (between 91% and 96%) along with salt, electrolytes, and waste products like urea and uric acid. For decades, the “gold standard” of urinalysis has focused on chemical and microscopic components or simple visual markers. For example, WebMD reports that urine color—ranging from pale yellow (normal) to dark orange (dehydration or liver issues)—provides a basic snapshot of systemic health. Other indicators, such as cloudy appearance or specific odors, often signal urinary tract infections or metabolic conditions like diabetes. The ASU research shifts the focus from these broad health indicators to highly specific microbial signatures. While Manchester Urology highlights how diet and medication can alter urine color, the MDM system looks past these superficial changes to find the metabolic by-products of the gut-brain axis. By leveraging the kidneys’ role in filtering the bloodstream, the MDM system treats urine as a biological ledger of what is happening in the gut. This allows for a non-invasive way to screen for neurological risk without the need for more invasive procedures or relying solely on the observation of behavioral milestones.

The Path Toward Early Intervention

The stakes for this technology are high. Earlier diagnosis of autism typically leads to earlier access to support services, which is widely recognized as a primary driver of better long-term outcomes. The transition of this research from the lab to the clinic is already moving. Christina Flynn, the study’s first author and a recent ASU PhD graduate, has transitioned into a role as the research director for the newly launched CLIA-certified Autism Diagnostics Laboratory. If the test maintains its accuracy in larger trials, it could transform the diagnostic pipeline. Rather than waiting for a child to struggle with social or linguistic milestones, a simple urine sample could flag high-risk children, allowing parents and providers to implement support systems years earlier than is currently possible.